Jazz’s shares rose 7.1% after the company reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised its 2026 revenue guidance. The early Ziihera launch and 35% oncology revenue growth were notable positives.
- Xywav sales increased 12% to $483 million; Jazz added approximately 425 net patients during the quarter across narcolepsy and idiopathic hypersomnia.
- Oncology revenue grew 35% year over year, with management citing Modeyso and first-line maintenance Zepzelca launches as drivers.
- Jazz completed its Actio Biosciences acquisition, adding the clinical-stage epilepsy candidate ABS-1230; initial patient data are expected at a medical meeting this quarter.
- Management said evolving competition from orexin 2 receptor agonists could lengthen the time some new patients take to initiate Xywav.
Community Discussion